
Novocure (NVCR) Stock Forecast & Price Target
Novocure (NVCR) Analyst Ratings
Bulls say
NovoCure Ltd has demonstrated positive financial momentum, reporting a 4% increase in 4Q25 revenue to $174.4 million and an 8% increase for full-year 2025 revenue to $655.4 million compared to the previous year. The company experienced notable growth in prescriptions for its Optune Lua device for non-small cell lung cancer (NSCLC) and reported strong domestic net sales of Optune Gio, contributing to a positive outlook for continued revenue growth in the U.S. and internationally, particularly with new national reimbursement in Spain expected to enhance revenue further in 2026.
Bears say
NovoCure Ltd has experienced a decline in revenue projections, with estimates for 2026 total revenue reduced to $711.3 million from a prior expectation of $738.9 million, driven by challenges in the launch of its NSCLC programs. Moreover, significant risks persist, including potential safety signals from ongoing clinical programs, competition from alternative treatments, and regulatory hurdles that could negatively influence revenue generation. Overall, the company's outlook is hindered by the possibility of lower than anticipated adoption rates for products like Optune, coupled with the downtrend in sales and adoption for its TTFields technology across multiple indications.
This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.
Novocure (NVCR) Analyst Forecast & Price Prediction
Start investing in Novocure (NVCR)
Order type
Buy in
Order amount
Est. shares
0 shares